Kahn Brothers Group Portfolio in 2026: Top Holdings & Recent Changes
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Kahn Brothers Group, led by Thomas Kahn and carrying forward the legendary value investing legacy of Irving Kahn, showcases its disciplined approach in the latest 13F filing. Their $564.7M portfolio for Q4 2025 emphasizes deep value plays across financials, healthcare, and media, with an extraordinary 84.1% concentration in the top 10 holdings and zero turnover signaling unwavering conviction in beaten-down names.
Portfolio Overview: Classic Value Discipline in Action
Portfolio Highlights (Q4’2025): - Market Value: $564.7M - Top 10 Holdings: 84.1% - Portfolio Size: 53 +0 - Average Holding Period: 17 quarters - Turnover: 0.0%
Kahn Brothers Group's portfolio exemplifies timeless value investing principles, with 84.1% of assets packed into just 10 positions despite maintaining 53 total holdings. This ultra-concentrated top tier, combined with a 17-quarter average holding period and zero turnover, underscores a patient strategy focused on undervalued businesses with strong fundamentals rather than chasing market momentum. The lack of new additions or exits beyond minor adjustments reflects confidence in current positions amid volatile markets.
The firm's approach prioritizes quality at a discount, spanning financials like Citigroup, healthcare giants such as Merck, and international names including BP. With such high concentration, Kahn Brothers demonstrates tolerance for short-term volatility in pursuit of long-term intrinsic value realization, a hallmark of the Kahn family's multi-decade track record. Investors tracking this $564.7M portfolio can glean insights into spotting opportunities others overlook.
Top Holdings: Financials Lead with Aggressive New Buys
The Kahn Brothers portfolio leads with Citigroup Inc. (C) at 18.1%, a bold new Buy position worth $102.3M signaling strong conviction in banking recovery plays. Close behind is Bayer AG Spons ADR (12.9%, $73.1M Buy), highlighting healthcare and ADR exposure, followed by Flagstar Financial, Inc. (FLG) at 9.3% ($52.6M Buy) as another fresh financial sector bet.
Healthcare strength continues with Merck & Co., Inc. (MRK) (8.0%, $45.3M Buy) and media via The Walt Disney Company (DIS) (7.9%, $44.9M Buy), both new positions emphasizing resilient consumer and pharma names. Tech enters with Alphabet Inc. (GOOG) (7.5%, $42.5M Buy), while energy sees a trim in BP p.l.c. (BP) (6.4%, $36.1M, Reduce 8.05%). Rounding out the top tier are Seaboard Corp (5.7%, $32.4M Buy), Organon & Co. (OGN) (4.6%, $26.0M Buy), and IDT Corporation (IDT) (3.6%, $20.1M Buy), showcasing a mix of industrials, biotech, and telecom value hunts.
These moves, all captured in the Q4 2025 portfolio, prioritize companies trading at discounts to intrinsic value, with "Buy" actions dominating except for the tactical BP reduction.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
What the Portfolio Reveals
Kahn Brothers' positioning reveals a classic value strategy honed over decades: - Quality over growth: Emphasis on established firms like Merck and Disney with durable moats, bought at depressed prices rather than high-flyers. - Sector focus: Heavy tilt to financials (Citigroup, Flagstar) and healthcare (Bayer, Merck, Organon), sectors ripe for mean reversion post-downturns. - Geographic concentration: U.S.-centric with international flavor via Bayer ADR and BP, balancing domestic recovery with global diversification. - Dividend strategy: Holdings like BP and Merck offer yields, supporting income amid low turnover. - Risk management approach: 84% top 10 concentration demands deep conviction, mitigated by 17-quarter holds and broad 53-position base.
This blend signals optimism for cyclical recovery without abandoning defensive quality.
Portfolio Concentration Analysis
| Position | Value | % of Portfolio | Recent Change |
|---|---|---|---|
| Citigroup Inc. | $102.3M | 18.1% | Buy |
| Bayer AG Spons ADR | $73.1M | 12.9% | Buy |
| Flagstar Financial, Inc. | $52.6M | 9.3% | Buy |
| Merck & Co., Inc. | $45.3M | 8.0% | Buy |
| The Walt Disney Company | $44.9M | 7.9% | Buy |
| Alphabet Inc. | $42.5M | 7.5% | Buy |
| BP p.l.c. | $36.1M | 6.4% | Reduce 8.05% |
| Seaboard Corp | $32.4M | 5.7% | Buy |
| Organon & Co. | $26.0M | 4.6% | Buy |
| IDT Corporation | $20.1M | 3.6% | Buy |
This table highlights Kahn Brothers' hallmark concentration, with the top 10 commanding 84.1% of the $564.7M portfolio—a level that amplifies returns from winners like Citigroup but demands precise selection. The nine "Buy" actions versus one reduction indicate aggressive deployment into perceived bargains, aligning with zero overall turnover and a patient 17-quarter horizon.
Such focus reduces diversification dilution, allowing outsized impact from high-conviction picks in financials and healthcare, while the single BP trim shows disciplined profit-taking in energy.
Investment Lessons from Kahn Brothers Group
- Concentrate on deep value: 84% in top 10 proves betting big on understood businesses when margins of safety are wide.
- Patience trumps trading: 17-quarter average holds and 0% turnover emphasize letting intrinsic value compound over time.
- Hunt cyclicals at bottoms: New buys in Citigroup and Flagstar exemplify buying fear in beaten-down financials.
- Balance sectors thoughtfully: Mix of U.S. financials, healthcare, and selective internationals manages risk without chasing fads.
- Trim selectively: The BP reduction shows monitoring even long-term winners for optimal sizing.
Looking Ahead: What Comes Next?
With zero turnover and a stable 53 positions, Kahn Brothers appears poised to hold through volatility, potentially deploying into further financial or healthcare dips if valuations compress. The heavy top-10 weighting sets up for leveraged upside if cyclicals rebound, especially with cash positions implied by unchanged size. In a 2026 environment of moderating rates and economic uncertainty, their value focus positions well for mean reversion in undervalued sectors, while broad holdings provide ballast. Watch for opportunistic adds in similar distressed quality names.
FAQ about Kahn Brothers Group Portfolio
Q: What are the biggest changes in Kahn Brothers' Q4 2025 13F filing?
A: The portfolio features nine new "Buy" positions in the top 10, led by Citigroup (C) at 18.1% and Bayer at 12.9%, with a sole Reduce 8.05% in BP. Turnover remains 0.0%, indicating stability.
Q: Why is Kahn Brothers' portfolio so concentrated?
A: 84.1% in top 10 holdings reflects high-conviction value investing, prioritizing deep research on quality businesses at discounts over broad diversification, a strategy rooted in Irving Kahn's philosophy.
Q: What sectors does Kahn Brothers favor?
A: Financials (C, FLG), healthcare (MRK, OGN), and select media/tech like DIS and GOOG dominate, targeting undervalued cyclicals.
Q: How can I track Kahn Brothers' portfolio like a pro?
A: Use ValueSense's superinvestor tracker at https://valuesense.io/superinvestors/kahn-brothers for real-time 13F updates. Note the 45-day filing lag means Q4 data reflects end-2025 positions.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2026)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!